Harland S J, Cook P A, Fosså S D, Horwich A, Parkinson M C, Roberts J T, Stenning S P
Medical Research Council Testicular Tumour Working Party, London, UK.
Eur Urol. 1993;23(1):115-8; discussion 119. doi: 10.1159/000474578.
In a study aimed at evaluating risk factors for carcinoma in situ (CIS) in the contralateral testis of selected patients with testicular cancer, information from 89 patients who have had contralateral testicular biopsies is available. The biopsies were performed because of the coexistence of the previously established risk factors - atrophy of the remaining testis, or a history of maldescent. CIS was diagnosed in 13% of patients, the prevalence being the same for both open and needle biopsies. Compared to its overall prevalence in the contralateral testis in testicular cancer an increased risk of CIS has been found in clinically atrophic testes but has not been found for maldescent. Patients found to have CIS were younger than those in whom it was not detected.
在一项旨在评估特定睾丸癌患者对侧睾丸原位癌(CIS)风险因素的研究中,有89例接受对侧睾丸活检患者的信息可供使用。进行活检是因为存在先前确定的风险因素——剩余睾丸萎缩或隐睾病史。13%的患者被诊断为CIS,开放活检和穿刺活检的患病率相同。与睾丸癌患者对侧睾丸的总体患病率相比,临床上萎缩的睾丸发生CIS的风险增加,但隐睾患者未发现这种情况。发现患有CIS的患者比未检测到CIS的患者更年轻。